Monte Rosa Therapeutics, Inc. business relationships
Companies named in Monte Rosa Therapeutics, Inc.’s 10-K filed 2026-03-17, and public companies whose annual reports name Monte Rosa Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.6 / 10
- AI naming
- <1 / 100 Top 80% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in Monte Rosa Therapeutics, Inc.’s annual report 7
“The goods and services that the Company is obligated to deliver and perform under the 2025 Novartis Agreement will be accounted for under ASC 606 as they represent a transaction with a customer.” SEC filing
“Our patent portfolio related to our VAV1 program has been exclusively licensed to Novartis.” SEC filing
“worldwide rights to the programs shown in Figure 1 below, except for MGDs directed against VAV1 including MRT-6160, which we licensed to Novartis in October 2024, and the targets included in the Roche and Novartis relationships.” SEC filing
“In October 2024, we entered into a license agreement with Novartis, or the 2024 Novartis Agreement.” SEC filing
“Collaboration revenue represents amounts earned from our collaboration and license agreements with Roche and Novartis.” SEC filing
“We expect that our collaborator, Novartis, will initiate multiple Phase 2 studies of MRT-6160 in immune-mediated diseases in 2026.” SEC filing
“Roche collaboration and license agreement” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.